In preclinical studies, FXR agonists, such as obeticholic acid, have been approved for the treatment of primary biliary cholangitis and have shown promising therapeutic potential in intestinal diseases like IBD, although their side effects and tissue specificity require further optimization [474, 475]. Here, NR1H4 is linked to inflammatory bowel disease.